Klaria Pharma Holding AB (publ.) (KLAR.ST)
SEK 1.07
(-9.75%)
SEK 1.07
(-9.75%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | - SEK | -100.0% |
| 2022 | 342 Thousand SEK | -66.47% |
| 2021 | 1.02 Million SEK | 0.0% |
| 2020 | - SEK | -100.0% |
| 2019 | 130 Thousand SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - SEK | 0.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 Q4 | - SEK | 0.0% |
| 2023 FY | - SEK | -100.0% |
| 2022 Q3 | 848 Thousand SEK | 0.0% |
| 2022 FY | 342 Thousand SEK | -66.47% |
| 2022 Q2 | 848 Thousand SEK | 0.0% |
| 2022 Q1 | 848 Thousand SEK | -16.86% |
| 2022 Q4 | 342 Thousand SEK | -59.67% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 FY | 1.02 Million SEK | 0.0% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 Q4 | 1.02 Million SEK | 0.0% |
| 2020 Q2 | 130 Thousand SEK | 0.0% |
| 2020 FY | - SEK | -100.0% |
| 2020 Q4 | - SEK | -100.0% |
| 2020 Q1 | 130 Thousand SEK | 0.0% |
| 2020 Q3 | 130 Thousand SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | 130 Thousand SEK | 0.0% |
| 2019 Q4 | 130 Thousand SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | NaN% |
| AlzeCure Pharma AB (publ) | - SEK | NaN% |
| BioGaia AB (publ) | 26.35 Million SEK | 100.0% |
| Enzymatica AB (publ) | 24.88 Million SEK | 100.0% |
| Enorama Pharma AB (publ) | 303 Thousand SEK | 100.0% |
| Gabather AB (publ) | - SEK | NaN% |
| Moberg Pharma AB (publ) | 3.46 Million SEK | 100.0% |
| Nanexa AB (publ) | 2.08 Million SEK | 100.0% |
| Newbury Pharmaceuticals AB (publ) | - SEK | NaN% |
| ODI Pharma AB | - SEK | NaN% |
| Orexo AB (publ) | 448.4 Million SEK | 100.0% |
| Probi AB (publ) | 38.21 Million SEK | 100.0% |
| Swedencare AB (publ) | 1.44 Billion SEK | 100.0% |
| Swedish Orphan Biovitrum AB (publ) | 11.35 Billion SEK | 100.0% |
| Toleranzia AB | 850 Thousand SEK | 100.0% |
| Vivesto AB | 5.18 Million SEK | 100.0% |